eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
10/2002
vol. 6
 
Share:
Share:
abstract:

Genetically modified dendritic cells as a cancer treatment strategy

Andrzej Mackiewicz
,
Dariusz W. Kowalczyk
,
Małgorzata Mackiewicz-Wysocka
,
Piotr Grabarczyk
,
Piotr J. Wysocki

Współcz Onkol (2002), vol. 6, 10, 637-642
Online publish date: 2003/03/26
View full text Get citation
 
Dendritic cells (DCs), the most potent APCs have been discovered almost 30 years ago. Due to priming of antigen-specific immune responses mediated by CD4+ and CD8+ lymphocytes, DCs are crucial for the induction of adaptive immunity against cancer. Therefore, vaccination of cancer patients with DCs presenting tumor associated antigens (TAAs) have been believed to be a promising anti-cancer strategy. Until now multiple clinical trials have been carried out in order to evaluate the safety and efficacy of cancer vaccines based on antigen-pulsed DCs. However, pulsing of DCs with particular peptides has several disadvantages: (i) short-time duration of antigen-MHC complexes, (ii) requirement for matching of defined peptides with MHC complexes and (iii) exclusive presentation of single antigen epitopes.
Application of gene transfer technologies in the field of DCs-based vaccines made possible the development of novel, anti-cancer immunization strategies. In several animal models, DCs modified with genes encoding TAA or immunostimulatory proteins have been shown to be effective in induction of anti-tumor immune responses. Based on these encouraging results, a first clinical trial of vaccination of prostate cancer patients with gene modified DCs has been recently initiated.
keywords:

dendritic cell, genetic modification, cancer vaccine, cytokine, TAAs

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.